Cannenta announces first patients in human trials of their unique pro-angiogenic wound treatment. Cannenta has reached a major milestone with the commencement of its first human trial for its’ CANN001 (hydrogel dressings with 2dDR), designed to promote angiogenesis and accelerate would healing. Patients with diabetic foot ulcers are now being treated in a Phase 1 [...]
Cannenta has signed a Heads of Agreement with Tianjin Medis Continuing to build strategic engagements with value adding organisations around the world, Cannenta has signed a Heads of Agreement with Tianjin Medis for preparation and support in distributing wound care products in the Chinese market. Tianjin Medis is a successful medical products distribution business operating [...]
Cannenta has signed a Heads of Agreement with Nexgel Inc Cannenta has signed a Heads of Agreement with US based manufacturer, Nexgel Inc. for the supply of wound dressings under contract for Cannenta. Initially, Nexgel will be providing quantities of their electron-beam crosslinked polymer hydrogels containing Cannenta’s unique factor, 2dDR for use in preclinical and [...]
